Drug intelligence / Profile preview

recombinant RSV vaccine (CHO cell)

Development stage: Phase 1
Lead developer: Yikang Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

recombinant RSV vaccine (CHO cell) is a recombinant protein subunit vaccine being developed by Yikang Biotech (Suzhou) Co., Ltd. in collaboration with Jiangsu Recbio Technology Co., Ltd. (Recbio). The vaccine consists of a recombinant respiratory syncytial virus (RSV) fusion (F) glycoprotein stabilized in its prefusion conformation (PreF), expressed using a Chinese hamster ovary (CHO) cell system. It is developed in two formulations: a basic formulation and an adjuvanted formulation utilizing Recbio's proprietary novel adjuvant system. The vaccine is designed to prevent lower respiratory tract diseases (LRTD) caused by RSV infection in adults, particularly those aged 50 years and older. It is currently in Phase I clinical development in China.

Other names: recombinant respiratory syncytial virus vaccine (CHO cell)recombinant respiratory syncytial virus vaccine (CHO cell) (adjuvanted)recombinant RSV vaccine (CHO cell) (adjuvanted)重组呼吸道合胞病毒疫苗（CHO细胞）重组呼吸道合胞病毒疫苗（CHO细胞）（佐剂）

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on recombinant RSV vaccine (CHO cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant RSV vaccine (CHO cell).

Explore the full profile